CFGS
ZYNE

Concourse Financial Group Securities’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Concourse Financial Group Securities’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-501
Closed -$180 – 2477
2023
Q1 		$215 Hold
501
– – ﹤0.01% 2305
2022
Q4 		$265 Hold
501
– – ﹤0.01% 2255
2022
Q3 		$0 Buy
+501
New +$568 ﹤0.01% 2323

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BWP
Bernardo Wealth Planning Harleysville, Pennsylvania $585M AUM 17.72% 1-Year Est. Return

Concourse Financial Group Securities's ZYNE Position: Q2 2023 in Review

Concourse Financial Group Securities sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2023, closing a stake of 501 shares — an estimated $180 sold.

Concourse Financial Group Securities first reported a position in ZYNE in Q3 2022 and held it in 3 quarters. The position peaked at $265 in Q4 2022. 41 funds tracked by Wall St. Rank hold ZYNE as of Q2 2023.

  • Concourse Financial Group Securities reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2023 after selling out during the quarter.
  • Concourse Financial Group Securities sold 501 Zynerba Pharmaceuticals, Inc shares in Q2 2023, an estimated $180.
  • Concourse Financial Group Securities first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2022 and held it in 3 quarters.
  • Concourse Financial Group Securities's Zynerba Pharmaceuticals, Inc position peaked at $265 in Q4 2022.
  • 41 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2023.

Based on Concourse Financial Group Securities's 13F filing for Q2 2023, filed 10 Aug 2023.